^
    8ms
    Gencurix discloses clinical results of ‘liquid biopsy-based early diagnosis of colorectal cancer’ at ASCO (Gencurix Press Release)
    "Gencurix will disclose two colorectal cancer clinical research results using its self-developed molecular diagnostic test method at the 2024 American Society of Clinical Oncology (ASCO) annual conference held on May 31."
    Clinical data
    |
    COLO eDX • Droplex BRAF Mutation Test • Droplex KRAS Mutation Test
    1year
    Gencurix receives approval to sell 6 types of companion diagnostic products, Turkiye (Gencurix Press Release)
    "Six types of Gencurix' companion diagnostic tests (Droplex) have been approved for sale in Turkiye, covering most of the Droplex test portfolio in Romania, Colombia, and Germany."
    Non-US regulatory
    |
    Droplex BRAF Mutation Test • Droplex EGFR Mutation Test v2 • Droplex KRAS Mutation Test • Droplex PIK3CA Mutation Test • Droplex POLE Mutation Test • Droplex c-Met Exon14 Skipping Test
    over1year
    Gencurix signs a cancer diagnosis kit supply contract with Biotype (Gencurix Press Release)
    "Gencurix announced...that it had signed a local agency supply contract with German Biotype...Gencurix plans to supply the Dropplex diagnostic kit, a digital PCR-based cancer companion diagnostic product, to Germany and other European countries through Biotype. Gencurix received European in vitro diagnostic medical device certification (CE-IVD) for six Dropplex products."
    Licensing / partnership
    |
    Droplex BRAF Mutation Test • Droplex EGFR Mutation Test v2 • Droplex KRAS Mutation Test • Droplex PIK3CA Mutation Test • Droplex POLE Mutation Test • Droplex c-Met Exon14 Skipping Test
    over2years
    Gencurix acquires European certification for 6 types of cancer companion diagnosis 'Dropplex' (Gencurix Press Release)
    "Gencurix...announced on the 21st that it has obtained European certification (CE) for 6 types of 'Dropplex', a molecular diagnostic (PCR)-based cancer companion diagnostic product...Dropplex consists of products that target a total of six biomarkers (biomarkers) including lung cancer (EGFR v2, c-MET), colorectal cancer (KRAS), endometrial cancer (POLE), breast cancer (PIK3CA) and thyroid cancer (BRAF)."
    European regulatory
    |
    Droplex BRAF Mutation Test • Droplex EGFR Mutation Test v2 • Droplex KRAS Mutation Test • Droplex PIK3CA Mutation Test • Droplex POLE Mutation Test • Droplex c-Met Exon14 Skipping Test